Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

High-Throughput Process Development (HTPD) for AAV Production Parameter Screening

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

High-Throughput Process Development (HTPD) for AAV Production Parameter Screening

High-Throughput Process Development for AAV Production

CELL & GENE | RNA | BIOLOGICS

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Proven Intelligence in Vector Process Development.

Executive Summary

High-Throughput Process Development (HTPD) for adeno-associated virus (AAV) vectors employs miniaturized, parallel experimentation to rapidly screen a wide range of upstream and downstream manufacturing parameters. This data-driven methodology identifies optimal production conditions for specific AAV serotypes and transgenes, generating a robust process understanding that minimizes scale-up risk. By defining a scalable protocol early, this approach supports accelerated timelines, with a target of 18-24 months to IND submission. Franklin Biolabs executes these complex screening programs within its >100,000 sq ft of specialized laboratory space.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

Frequently Asked Questions

    What is HTPD for AAV manufacturing?

    HTPD is a systematic approach that uses small-scale, parallel culture systems like deep-well plates or mini-bioreactors to test numerous process conditions simultaneously. This allows for the rapid evaluation of variables such as media composition, transfection reagents, and purification resins to identify the most efficient and scalable combination for a given AAV vector.

    Which upstream and downstream parameters can be screened?

    A comprehensive design of experiment (DoE) can assess multiple variables. Upstream parameters include cell line selection, media formulations, feed strategies, and transfection conditions. Downstream screening can evaluate lysis buffers, clarification methods, and affinity or ion-exchange chromatography resins to maximize vector recovery and purity.

    How does HTPD de-risk the path to GxP manufacturing?

    HTPD generates a deep, multivariate dataset that defines a robust and reproducible manufacturing process. This process knowledge is valuable for technology transfer to GxP environments, as it establishes proven acceptable ranges for process parameters, reducing the likelihood of batch failures or delays at larger scales.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

The Challenge of AAV Process Variability

A manufacturing process optimized for one AAV serotype, such as AAV9, often requires significant modification to achieve comparable yield and purity for another, like an engineered capsid. Relying on platform processes without specific optimization can lead to inconsistent vector titers, poor full-to-empty capsid ratios, and unexpected impurity profiles. These issues create significant delays during IND-enabling activities.

A tailored, data-driven preclinical strategy is required to build a scalable and transferable AAV production process. This begins with systematically mapping the process design space.

A Systematic Approach to Parameter Screening

High-Throughput Process Development moves beyond iterative, one-factor-at-a-time experiments. It allows for a comprehensive evaluation of the variables that influence vector production and quality.

Our HTPD workflow includes:

  • Design of Experiment (DoE): Statistically mapping the interaction between multiple variables to efficiently screen the design space.

  • Miniaturized Bioreactor Systems: Employing parallel culture systems to model suspension or adherent processes at a small scale, conserving plasmid and cell resources.

  • Multi-Attribute Analytics: Integrating rapid, small-volume analytical methods to assess vector titer, particle concentration, and product quality attributes from each experimental condition.

From Data to a Definitive Process

The output of an HTPD program is a comprehensive dataset that defines a lead candidate process and informs all future scale-up activities. By understanding which parameters have the greatest impact on yield and quality, we can establish a control strategy that ensures consistency from 2L confirmation runs to 500L+ GxP production.

“The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Linking Process Control to Therapeutic Enablement

Establishing a robust manufacturing process is directly analogous to identifying predictive translational markers for a therapeutic program. Foundational work in other areas of advanced therapies has shown how identifying and monitoring key analytes can de-risk and accelerate clinical evaluation [PMID: 28934395]. In the same way, defining and controlling process parameters through HTPD provides the predictive power needed to ensure the consistent production of high-quality viral vectors. This manufacturing certainty is a prerequisite for successful IND-enabling toxicology studies and subsequent clinical development.

Technical Visualization: High-Throughput AAV Process Development Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities